Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million

By Judy Newman, Wisconsin State Journal

Amgenarrowhead-research-logo-tw_400x400, one of the world’s leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start with the potential for another $600 million or more in the future.

Arrowhead is based in Pasadena, California but most of its research is conducted in Madison, at 465 Science Drive, where the company has about 90 employees.

“This is a very important partnership for us,” said Arrowhead president and CEO Christopher Anzalone, in a conference call with analysts. “We are thrilled to be working with Amgen.

Arrowhead is working on a variety of drugs based on RNA interference (RNAi), in which molecules can silence targeted genes associated with certain diseases. Read more …
Comments are closed.

Facebook IconYouTube IconTwitter IconVisit Our LinkedIn Profile